Adherex Technologies (NASDAQ:FENC) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint [Yahoo! Finance]
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference